

Meury William
Form 4
February 16, 2018

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Meury William

(Last) (First) (Middle)

CLONSHAUGH BUSINESS AND
TECHNOLOGY
PARK., COOLOCK, CO.

(Street)

DUBLIN, L2 D17 E400

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol

Allergan plc [AGN]

3. Date of Earliest Transaction
(Month/Day/Year)

02/14/2018

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

____ Director ____ 10% Owner
X Officer (give title ____ Other (specify
below) below)

Chief Commercial Officer

6. Individual or Joint/Group Filing(Check
Applicable Line)
X Form filed by One Reporting Person
____ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares, par value \$0.0001	02/14/2018		M	1,957 A \$ 51.07	56,944 ⁽¹⁾ ⁽²⁾	D	
Ordinary Shares, par value \$0.0001	02/14/2018		M	2,765 A \$ 51.07	59,709 ⁽²⁾	D	
Ordinary Shares, par value	02/14/2018		M	1,510 A \$ 66.2	61,219 ⁽²⁾	D	

Edgar Filing: Meury William - Form 4

\$0.0001

Ordinary Shares, par value	02/14/2018	M	17,381	A	\$ 66.2	78,600 ⁽²⁾	D
----------------------------------	------------	---	--------	---	---------	-----------------------	---

\$0.0001

Ordinary Shares, par value	02/14/2018	S	25,079	D	\$ 157.18 ⁽³⁾	53,521 ⁽²⁾	D
----------------------------------	------------	---	--------	---	--------------------------------	-----------------------	---

\$0.0001

Ordinary Shares, par value	02/14/2018	S	1,200	D	\$ 157.6 ⁽⁴⁾	52,321 ⁽²⁾	D
----------------------------------	------------	---	-------	---	----------------------------	-----------------------	---

\$0.0001

Ordinary Shares, par vaule	02/14/2018	S	1,700	D	\$ 158.78 ⁽⁵⁾	50,621 ⁽²⁾	D
----------------------------------	------------	---	-------	---	--------------------------------	-----------------------	---

\$0.0001

Ordinary Shares, par value	02/14/2018	S	2,400	D	\$ 159.82 ⁽⁶⁾	48,221 ⁽²⁾	D
----------------------------------	------------	---	-------	---	--------------------------------	-----------------------	---

\$0.0001

Ordinary Shares, par vaule	02/14/2018	S	1,000	D	\$ 161.1 ⁽⁷⁾	47,221 ⁽²⁾	D
----------------------------------	------------	---	-------	---	----------------------------	-----------------------	---

\$0.0001

Ordinary Shares, par value	02/14/2018	S	4,700	D	\$ 162.22 ⁽⁸⁾	42,521 ⁽²⁾	D
----------------------------------	------------	---	-------	---	--------------------------------	-----------------------	---

\$0.0001

Ordinary Shares, par value	02/14/2018	S	7,200	D	\$ 163.04 ⁽⁹⁾	35,321 ⁽²⁾	D
----------------------------------	------------	---	-------	---	--------------------------------	-----------------------	---

\$0.0001

Ordinary Shares, par value	02/14/2018	S	2,000	D	\$ 164.62 ⁽¹⁰⁾	33,321 ⁽²⁾	D
----------------------------------	------------	---	-------	---	---------------------------------	-----------------------	---

\$0.0001

Ordinary Shares, par value	02/14/2018	S	13,600	D	\$ 165.16 ⁽¹¹⁾	19,721 ⁽²⁾	D
----------------------------------	------------	---	--------	---	---------------------------------	-----------------------	---

\$0.0001

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of
information contained in this form are not
required to respond unless the form**

SEC 1474
(9-02)

displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount Underlying Security (Instr. 3 and 4)	Amount or Number of Shares
Incentive Stock Option	\$ 51.07	02/14/2018		M	1,957	<u>(12)</u> 12/07/2018	Ordinary Shares	1,957
Non-Qualified Options to Purchase Common Stock	\$ 51.07	02/14/2018		M	2,765	<u>(13)</u> 12/07/2018	Ordinary Shares	2,765
Incentive Stock Option	\$ 66.2	02/14/2018		M	1,510	<u>(14)</u> 12/06/2019	Ordinary Shares	1,510
Non-Qualified Options to Purchase Common Stock	\$ 66.2	02/14/2018		M	17,381	<u>(15)</u> 12/06/2019	Ordinary Shares	17,381

Reporting Owners

Reporting Owner Name / Address	Relationships
Meury William CLONSHAUGH BUSINESS AND TECHNOLOGY PARK, COOLOCK, CO. DUBLIN, L2 D17 E400	Director 10% Owner Officer Other Chief Commercial Officer

Signatures

/s/ A. Robert D. Bailey, Attorney-in-Fact for the Reporting
Person

02/16/2018

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The total number of shares reported has been reduced by 423 due to prior inadvertent over-reporting of shares beneficially owned by the Reporting Person.
- (2) Includes restricted shares issued pursuant to the 2013 Incentive Award Plan of Allergan plc.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$156.29 to \$157.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- (3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$157.30 to \$158.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- (4) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$158.30 to \$159.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- (5) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$159.41 to \$160.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- (6) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$160.59 to \$161.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- (7) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$161.67 to \$162.64, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- (8) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$162.68 to \$163.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- (9) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$164.04 to \$165.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- (10) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from \$165.05 to \$165.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- (11) The option vested on December 8, 2013.
- (12) The option vested in five equal installments on December 8, 2009, 2010, 2011, 2012 and 2013.
- (13) The option vested on December 7, 2014.
- (14) The option vested in five equal installments on December 7, 2010, 2011, 2012, 2013 and 2014.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.